The combination of pivmecillinam and pivampicillin in the treatment of enteric fever.
Thirty-nine patients with acute enteric fever received the fixed-dose oral combination of pivmecillinam/pivampicillin. Thirty-seven (95%) subjects responded satisfactorily. No relapses or persistent faecal excretion of salmonellae were seen in the 29 patients followed up for 2 to 19 weeks. The treatment was well tolerated, no side-effects being recorded. In vitro studies revealed a synergistic interaction between mecillinam and ampicillin against isolates of Salmonella paratyphi A.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000560:Amdinocillin / Q000008:administration & dosage*; D000561:Amdinocillin Pivoxil / Q000008:administration & dosage*; D000667:Ampicillin / Q000031:analogs & derivatives*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010403:Penicillin Resistance; D010917:Pivampicillin / Q000008:administration & dosage*; D012475:Salmonella / Q000187:drug effects; D014435:Typhoid Fever / Q000188:drug therapy*
D004338:Drug Combinations; D010917:Pivampicillin; D000561:Amdinocillin Pivoxil; D000667:Ampicillin; D000560:Amdinocillin